Artificial Intelligence in Andrology: From Semen Analysis to Image Diagnostics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghayda Ramy Abou, Cannarella Rossella, Calogero Aldo E, Shah Rupin, Rambhatla Amarnath, Zohdy Wael, Kavoussi Parviz, Avidor-Reiss Tomer, Boitrelle Florence, Mostafa Taymour, Saleh Ramadan, Toprak Tuncay, Birowo Ponco, Salvio Gianmaria, Calik Gokhan, Kuroda Shinnosuke, Kaiyal Raneen Sawaid, Ziouziou Imad, Crafa Andrea, Phuoc Nguyen Ho Vinh, Russo Giorgio I, Durairajanayagam Damayanthi, Al-Hashimi Manaf, Hamoda Taha Abo-Almagd Abdel-Meguid, Pinggera Germar-Michael, Adriansjah Ricky, Maldonado Rosas Israel, Arafa Mohamed, Chung Eric, Atmoko Widi, Rocco Lucia, Lin Haocheng, Huyghe Eric, Kothari Priyank, Solorzano Vazquez Jesus Fernando, Dimitriadis Fotios, Garrido Nicolas, Homa Sheryl, Falcone Marco, Sabbaghian Marjan, Kandil Hussein, Ko Edmund, Martinez Marlon, Nguyen Quang, Harraz Ahmed M, Serefoglu Ege Can, Karthikeyan Vilvapathy Senguttuvan, Tien Dung Mai Ba, Jindal Sunil, Micic Sava, Bellavia Marina, Alali Hamed, Gherabi Nazim, Lewis Sheena, Park Hyun Jun, Simopoulou Mara, Sallam Hassan, Ramirez Liliana, Colpi Giovanni, Agarwal Ashok, Global Andrology Forum
Аннотация
METHODS: All 22 confirmed cases were investigated descriptively, and a case-control study was conducted involving 22 cases and 44 controls. Participant information, including vaccination history, was obtained through a field epidemiological investigation.
RESULTS: The epidemic curve of the 22 cases indicated a human-to-human transmission, with 16 transmission routes identified through the investigation. The average time from symptom onset to diagnosis was 8 days (3 to 30 days). Eight cases (36.4%) had completed all six doses of vaccination, including the final Tdap booster. In the control group, 28 out of 44 individuals (63.6%) had received the Tdap booster. A marginal statistical difference was observed between the groups (P = 0.065). Among the eight cases, the mean interval between Tdap vaccination and symptom onset was 23.1 ± 11.1 months, compared to 13.3 ± 9.0 months until the end of the outbreak for the 28 controls (P = 0.014).
CONCLUSION: These findings suggest that individuals who did not receive the Tdap booster may be more susceptible to pertussis infection. It is necessary to consider standardizing the final adolescent booster as Tdap within Korea's National Immunization Program. Health authorities should use nationwide data to address the implications of permitting both Tdap and Td as the final booster dose and resolve the inconsistencies in current guidelines. While this manuscript was under review, the guideline was updated in March 2025 to recommend Tdap, not Td, as the booster at 11-12 years of age.